Eupraxia Pharmaceuticals Inc experienced a notable uptick in its stock price, reflecting investor optimism.
Eupraxia Pharmaceuticals Inc (EPRX.TO) saw its stock price increase by 6.49% in yesterday's trading session, closing at CA$10.99. This surge comes amid positive investor sentiment, likely fueled by the company's recent developments.
Investor takeaway: Keep an eye on Eupraxia's ongoing projects and market movements as the company continues to evolve in the pharmaceutical sector.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$681.88M
52W high
$13.08
52W low
$7.35
1W change
-5.67%
Beta
1.49
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 48.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+48.6% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$10.99
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
96.6%
Annualized
90-Day Vol
70.0%
Annualized
Trend (90d)
+48.1%
Annualized drift
90d Mean
C$13.05
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.64 | C$8.34 – C$16.24 |
| 60 trading days | C$12.32 | C$7.69 – C$19.75 |
| 90 trading days | C$13.05 | C$7.33 – C$23.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Eupraxia Pharmaceuticals Inc stock up 6.49%
The stock's increase reflects a market cap of CA$681.88 million, showcasing investor interest in its growth potential.
Bull case
The recent rise in Eupraxia's stock price suggests growing confidence in its pipeline, especially regarding its lead program, EP-104GI, which has shown promising clinical results.
Bear case
Even with the positive movement, investors should stay cautious. The pharmaceutical industry can be volatile, and any setbacks in clinical trials could affect stock performance.
Advertisement
Market Reaction
The 6.49% increase in Eupraxia's stock price reflects a strong market reaction to the company's ongoing developments and potential in the pharmaceutical sector. Investors seem optimistic about the future, particularly regarding the progress of EP-104GI.
Looking Ahead
As Eupraxia advances its clinical programs, investors should closely monitor upcoming announcements and financial results. The company's ability to deliver on its promises will be crucial for maintaining investor confidence and stock performance. For more insights, check out our analysis on Eupraxia Pharmaceuticals.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
